Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cancer: a cohort-based study.

Date publication

juin 2025

Journal

The oncologist

Auteurs

Membres identifiés du Cancéropôle Est :
Mme POZET Astrid

Tous les auteurs :
Evrard C, Pelras A, Rivet S, Bachet JB, Dubreuil O, Pointet AL, Taieb J, Lahlou W, Portal A, Lepère C, Lecomte T, Chautard R, Williet N, Phelip JM, Coutzac C, Soularue E, Marthey L, Abdallah R, Thirot Bidault A, Artru P, Desrame J, Le Roy B, Jary M, Hammel P, Trouilloud I, Lourenco N, Hautefeuille V, Dahan L, Pernot S, Béchade D, Pozet A, Bonnetain F, Locher C, Dréanic J, Coriat R, Tchoundjeu B, Foucher Y, Tougeron D

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40515476

Résumé

Advanced pancreatic ductal adenocarcinoma (aPDAC) has a poor prognosis with median overall survival (OS) of about 12 months. It is therefore important to explore factors that predict the efficacy of third-line chemotherapy (L3) to identify patients who may benefit from this controversial treatment.

Mots clés

cohort, pancreatic cancer, predictive factors, third-line chemotherapy

Référence

Oncologist. 2025 06 4;30(6):